Panel discussion: Business of bioanalysis with Bioanalysis Zone
Bioanalysis Zone and Bioanalysis had the opportunity to host a panel discussion with experts from leading pharmaceutical companies and CROs to discuss several contemporary topics. Tese included emerging technologies; recruiting and talent development; and mergers and acquisitions. We thank our contributing experts Scott Fountain (Charles River Laboratories), Zamas Lam (QPS), Roger Hayes (MPI Research), Yan Zhang (Bristol-Myers Squibb), Ola Saad (Genentech), and Afshin Safavi (BioAgilytix) for their time and thoughtful contributions.
The full discussion was broken into three episodes, which included subjects such as:
Investing in emerging bioanalytical technolo- gies – when is too soon and when is too late? Acquisition of new tools to address unmet ana- lytical needs
requires practical considerations,
such as platform reliability, scalability from dis- covery to the regulated environment and total cost of ownership. This includes hiring and training appropriate subject matter experts, man- aging software validation and accurately reading the bioanalytical marketplace.
Managing the pipeline of bioanalytical talent and staff, including recruiting, training and retaining key analytical experts. Universities are not the singular source generating talent in bioanalysis skill sets. Beyond compensation, con- tinuous education, cross-training, job rotations, and customized recognition models within the laboratory are critical to enticing and retaining ‘the best’ in our CRO and pharmaceutical orga- nizations.
Mentorship of colleagues in the bioanalytical sciences, which has evolved from a data gener- ating role to a multidisciplinary science over the years. Bioanalysis as a path to broader leadership opportunities requires mentorship across differ- ent areas – science, the drug development pro- cess, leadership and emotional ‘soft skills’. This is particularly relevant in the CRO-pharmaceutical partnership when working with diverse teams, colleagues and clients.
The impact of mergers, acquisitions, and organic growth on bioanalytical sciences. The scientific community in which we work goes beyond affiliation, movement of bioanalytical scientists and talent between CRO, pharmaceu- tical and instrument vendors. The business is robust, while management of corporate culture is critical.
You can access the full panel discussion, here:
www.bioanalysis-zone.com/2017/09/01/bio- analysis-zone-panel-discussion-bob2017/
www.bioanalysis-zone.com
48
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58
